HK1145322A1 - - Google Patents

Info

Publication number
HK1145322A1
HK1145322A1 HK10111709.7A HK10111709A HK1145322A1 HK 1145322 A1 HK1145322 A1 HK 1145322A1 HK 10111709 A HK10111709 A HK 10111709A HK 1145322 A1 HK1145322 A1 HK 1145322A1
Authority
HK
Hong Kong
Prior art keywords
amides
preparing
relates
present
novel
Prior art date
Application number
HK10111709.7A
Other languages
English (en)
Inventor
Olivier Loiseleur
Daniel Kaufmann
Stephan Abel
Hans Michael Buerger
Mark Meisenbach
Beat Schmitz
Gottfried Sedelmeier
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of HK1145322A1 publication Critical patent/HK1145322A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10111709.7A 2002-02-07 2005-04-28 HK1145322A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202873.6A GB0202873D0 (en) 2002-02-07 2002-02-07 Organic compounds

Publications (1)

Publication Number Publication Date
HK1145322A1 true HK1145322A1 (fr) 2011-04-15

Family

ID=9930607

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05103664.4A HK1070893A1 (fr) 2002-02-07 2005-04-28
HK10111709.7A HK1145322A1 (fr) 2002-02-07 2005-04-28

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK05103664.4A HK1070893A1 (fr) 2002-02-07 2005-04-28

Country Status (26)

Country Link
US (8) US7456283B2 (fr)
EP (2) EP1474408B1 (fr)
JP (2) JP4653954B2 (fr)
KR (1) KR101027044B1 (fr)
CN (2) CN101016262A (fr)
AU (1) AU2003244444B2 (fr)
BR (2) BRPI0307529B1 (fr)
CA (2) CA2474738C (fr)
CO (1) CO5601018A2 (fr)
CY (2) CY1112938T1 (fr)
DK (2) DK1474408T3 (fr)
EC (2) ECSP045220A (fr)
ES (2) ES2384872T3 (fr)
GB (1) GB0202873D0 (fr)
HK (2) HK1070893A1 (fr)
IL (3) IL163158A (fr)
MX (1) MXPA04007642A (fr)
NO (2) NO327366B1 (fr)
NZ (3) NZ569731A (fr)
PL (1) PL209475B1 (fr)
PT (2) PT1474408E (fr)
RU (2) RU2370493C2 (fr)
SG (1) SG160195A1 (fr)
SI (2) SI1474408T1 (fr)
WO (1) WO2003066613A1 (fr)
ZA (1) ZA200405970B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2003242988A1 (en) * 2003-06-06 2005-01-04 Adibhatla Kali Sathya Bhujanga Rao Process for the preparation of the anti-cancer drug imatinib and its analogues
WO2004110452A1 (fr) * 2003-06-13 2004-12-23 Novartis Ag Derives de 2-aminopyrimidine utilises comme inhibiteurs de raf kinase
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
CN101951889A (zh) * 2006-09-01 2011-01-19 特瓦制药工业有限公司 伊马替尼组合物
DE602007012122D1 (de) 2006-09-22 2011-03-03 Novartis Ag Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib
EP2009008A1 (fr) 2006-10-26 2008-12-31 Sicor, Inc. Base d'imatinib, et mesylate d'imatinib et son procédé de préparation
EP1966186A1 (fr) * 2006-10-26 2008-09-10 Sicor Inc. Procédé pour la préparation d'imatinib
US8168787B2 (en) * 2006-11-16 2012-05-01 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the preparation of imatinib and intermediates thereof
CN100451015C (zh) * 2007-02-14 2009-01-14 杭州盛美医药科技开发有限公司 一种伊马替尼的制备方法
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
CA2689989A1 (fr) * 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Composes heterocycliques et utilisations de ceux-ci
US8414918B2 (en) * 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
WO2009080366A1 (fr) * 2007-12-22 2009-07-02 Synthon B.V. Procédé de fabrication d'imatinib
CN101497601B (zh) * 2008-01-29 2012-11-07 福建南方制药股份有限公司 伊马替尼的合成方法
PL215042B1 (pl) * 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania imatinibu
KR20100021321A (ko) * 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
EP2370078A1 (fr) 2008-12-01 2011-10-05 Novartis AG Méthode d optimisation du traitement de la leucémie philadelphie positive avec du mésylate d imatinib
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CN101654416B (zh) * 2009-09-16 2013-06-05 成都神黄医药科技开发有限公司 N-[3-硝基-4-甲基-苯基]-4-醛基-苯甲酰胺及其制备方法以及其衍生物的制备方法
US20110306763A1 (en) 2009-12-10 2011-12-15 Shanghai Parling Pharmatech Co., Ltd. Process for the preparation of imatinib and salts thereof
WO2011095835A1 (fr) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Imatinib de grande pureté ou un sel pharmaceutiquement acceptable de celui-ci
US8609842B2 (en) 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
SI2582689T1 (sl) 2010-06-18 2017-05-31 Krka, D.D., Novo Mesto Nova polimorfna oblika imatinib baze in priprava njenih soli
TR201007005A2 (tr) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
WO2013035102A1 (fr) 2011-09-05 2013-03-14 Natco Pharma Limited Procédés pour la préparation d'imatinib sous forme de base et leurs intermédiaires
JP2014532647A (ja) 2011-10-28 2014-12-08 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
CN102827144A (zh) * 2012-09-05 2012-12-19 湖南欧亚生物有限公司 一种伊马替尼的制备方法
RU2537398C1 (ru) * 2013-08-20 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный технологический университет" (СибГТУ) Гексазамещенные пара-аминофенолы с ариламидными группами в 2,6-положениях по отношению к гидроксилу
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
US20190247338A1 (en) 2016-10-17 2019-08-15 Delta-Fly Pharma, Inc. Pharmaceutical composition for treatment or remission of chronic myelogenous leukemia
WO2018089404A1 (fr) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Procédés de production de germanium-68 comportant des substances volatiles réduites
EP3333162A1 (fr) 2016-12-12 2018-06-13 Silesian Catalysts sp. z o.o. Procede de preparation de n(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
AU2018336171B2 (en) 2017-09-22 2023-01-05 Jubilant Epipad LLC Heterocyclic compounds as PAD inhibitors
CA3076476A1 (fr) 2017-10-18 2019-04-25 Jubilant Epipad LLC Composes imidazo-pyridine a utiliser en tant qu'inhibiteurs de pad
WO2019087214A1 (fr) 2017-11-06 2019-05-09 Jubilant Biosys Limited Dérivés de pyrimidine utilisés en tant qu'inhibiteurs de l'activation de pd1/pd-l1
KR20200092346A (ko) 2017-11-24 2020-08-03 주빌런트 에피스크라이브 엘엘씨 Prmt5 억제제로서의 헤테로사이클릭 화합물
CN108164505B (zh) * 2018-01-16 2020-11-03 扬州大学 一种伊马替尼的合成方法
WO2019152977A2 (fr) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Résine de chromatographie ayant un ligand mode mixte échange anionique/hydrophobe
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE531480C (de) * 1929-07-03 1931-08-10 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Aryliden einer unsymmetrischen o-Xylenolcarbonsaeure
US2808433A (en) * 1953-08-21 1957-10-01 Du Pont Benzene dicarboxylic acid derivatives
GB862127A (en) * 1958-07-04 1961-03-01 Ici Ltd Derivatives of 2-hydroxy-3-naphthanilide
US3505433A (en) * 1965-03-08 1970-04-07 Hooker Chemical Corp 2-haloperfluoro-1-cycloalken-1-ylphosphoryl compounds
US3505389A (en) * 1966-08-18 1970-04-07 Hooker Chemical Corp 4-amino-2,3,5,6-tetrachlorobenzoic acid and derivatives thereof
US3505398A (en) 1966-09-22 1970-04-07 Standard Oil Co Terephthalic acid crystallization
US3763234A (en) * 1970-12-03 1973-10-02 Halcon International Inc Preparation of amides
JPS4987761U (fr) 1972-11-17 1974-07-30
JPS563375B2 (fr) * 1972-12-25 1981-01-24
JPS5720923B2 (fr) * 1974-04-02 1982-05-04
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
JPS5665804A (en) * 1979-11-01 1981-06-03 Ishihara Sangyo Kaisha Ltd Control agent against injurious organism
DE3305755A1 (de) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
US4623486A (en) 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
JP2894804B2 (ja) * 1989-07-19 1999-05-24 武田薬品工業株式会社 ２―アミノ―５―メチルベンゾフェノン類及びその製造法
JPH03130252U (fr) 1990-04-11 1991-12-27
FR2664895B1 (fr) * 1990-07-20 1992-10-30 Theramex Laboratoire Nouveaux derives de la 6-methyl 19-nor progesterone, substitues en 3 et leur procede d'obtention.
DE4110483A1 (de) * 1991-03-30 1992-10-01 Bayer Ag Substituierte salicylamide, mittel gegen pflanzenkrankheiten
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
FR2689925B1 (fr) 1992-04-08 1994-05-27 Valeo Securite Habitacle Dispositif de verrouillage d'une serrure dans son support.
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DE4428380A1 (de) 1994-08-11 1996-02-15 Bayer Ag 4-Trifluormethylbenzamide
JPH0987761A (ja) 1995-09-22 1997-03-31 Nikko Kinzoku Kk 銅転炉スラグからの銅の回収方法
JP3130252B2 (ja) 1996-07-12 2001-01-31 小糸工業株式会社 座席のヘッドレスト装置
DK0994875T3 (da) * 1997-06-30 2004-06-21 Targacept Inc 3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
BR9910474A (pt) * 1998-05-15 2001-01-02 Astrazeneca Ab Composto derivado de amida, processo para preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
ES2211172T3 (es) 1998-09-25 2004-07-01 Astrazeneca Ab Derivados de benzamida y su utilizacion como inhibidores de citoquinas.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
EP2248807A1 (fr) 2010-11-10
IL189658A (en) 2011-05-31
GB0202873D0 (en) 2002-03-27
HK1070893A1 (fr) 2005-06-30
US20150018552A1 (en) 2015-01-15
CY1112938T1 (el) 2016-04-13
SI2248807T1 (sl) 2013-10-30
JP4653954B2 (ja) 2011-03-16
RU2004126941A (ru) 2005-10-10
NO327366B1 (no) 2009-06-15
RU2007148217A (ru) 2009-07-10
US20070293683A1 (en) 2007-12-20
US20120226039A1 (en) 2012-09-06
IL189658A0 (en) 2008-06-05
JP2005528340A (ja) 2005-09-22
NO20091976L (no) 2004-11-05
RU2370493C2 (ru) 2009-10-20
EP1474408A1 (fr) 2004-11-10
AU2003244444B2 (en) 2007-08-09
AU2003244444B9 (en) 2003-09-02
CA2737565A1 (fr) 2003-08-14
SG160195A1 (en) 2010-04-29
ES2425980T3 (es) 2013-10-18
EP2248807B1 (fr) 2013-07-03
CO5601018A2 (es) 2006-01-31
US7579467B2 (en) 2009-08-25
ZA200405970B (en) 2006-05-31
DK2248807T3 (da) 2013-08-26
US20090137805A1 (en) 2009-05-28
NZ554430A (en) 2008-08-29
DK1474408T3 (da) 2012-06-25
IL189657A (en) 2010-12-30
CA2474738C (fr) 2011-10-04
KR20040081154A (ko) 2004-09-20
KR101027044B1 (ko) 2011-04-11
NO20043685L (no) 2004-11-05
IL163158A (en) 2010-11-30
PL209475B1 (pl) 2011-09-30
US20070293673A1 (en) 2007-12-20
AU2003244444A1 (en) 2003-09-02
MXPA04007642A (es) 2004-11-10
SI1474408T1 (sl) 2012-07-31
CY1114351T1 (el) 2016-08-31
CN101016262A (zh) 2007-08-15
US7816359B2 (en) 2010-10-19
EP1474408B1 (fr) 2012-05-23
US20070293672A1 (en) 2007-12-20
BR0307529A (pt) 2004-12-21
PT1474408E (pt) 2012-07-25
CN1630648A (zh) 2005-06-22
US7456283B2 (en) 2008-11-25
NZ534315A (en) 2007-06-29
NZ569731A (en) 2009-11-27
US20060142580A1 (en) 2006-06-29
CA2737565C (fr) 2013-04-09
JP2010138194A (ja) 2010-06-24
US9573928B2 (en) 2017-02-21
ECSP045220A (es) 2004-09-28
ES2384872T3 (es) 2012-07-13
WO2003066613A1 (fr) 2003-08-14
US7825247B2 (en) 2010-11-02
BRPI0307529B1 (pt) 2018-01-30
IL189657A0 (en) 2008-06-05
CN100347162C (zh) 2007-11-07
CA2474738A1 (fr) 2003-08-14
PT2248807E (pt) 2013-09-02
ECSP095220A (es) 2009-08-28
PL371197A1 (en) 2005-06-13
US20070293504A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
HK1145322A1 (fr)
GB0119795D0 (en) Novel process
GB0504952D0 (en) Process for producing arylamine
TWI318627B (en) Improved process for carbapenem synthesis
MXPA03010322A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE POLIISOCIANATOS.
MXPA03004986A (es) Proceso para preparar polimeros de emulsion con alta pureza.
SI1403264T1 (en) Process for the industrial synthesis of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxydimethylester
SG99415A1 (en) Process for producing diamines
IL162059A0 (en) Process for the synthesis of -amino- chirally purealcohols
PL364554A1 (en) Process for the production of nylon 6
IL159836A0 (en) Process for obtaining n-monosubstituted amides
PL372214A1 (en) Novel process
MXPA03009091A (es) Amidas novedosas del acido n-p-propargiloxifenetil-tioacetico.
IL141049A0 (en) Methoximinophenylacetic acid amides
GB0126768D0 (en) Novel process
EG23417A (en) Process for the preparation 7 a-methylsteroids.
TWI319392B (fr)
PL352935A1 (en) Method for producing elastic bands for the clothing industry
GB0206655D0 (en) Novel process
GB0229476D0 (en) Novel process
AU2003238198A8 (en) Method for producing 4,6-dichloro-5-fluoropyrimidine
PL374000A1 (en) Improved process for hydroxyazapirones
PL372922A1 (en) Novel o-isopropylisourea salts and process for the production thereof
AP2003002772A0 (en) Novel substituted 1, 2, 4-trixanes useful as antimatarial agents and a process for the preparation hereof
IL161800A0 (en) Method for the production of desclarithromycin, and intermediateproducts

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200202